41.72
-0.31%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Chengdu Easton Biopharmaceuticals Co
Its shares trade on Shanghai under the ticker 688513.SS. It has been listed since 2 September 2020. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.33bn and net income of CN¥283.2m. At that date it held total assets of CN¥3.80bn and shareholders' equity of CN¥2.87bn.
Chengdu Easton Bio Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of chemical raw materials and chemical drug preparations. The company is headquartered in Chengdu, Sichuan. The company went IPO on 2020-09-02. The firm's main products are chemical generic drugs. Its products include nalmefene hydrochloride injection, caffeine citrate injection, ibuprofen injection, bisoprolol fumarate tablets, ubenimex, etc. Its products are used in the fields of anesthesia and analgesia, cardiovascular, anti-tumor, digestion and children's medicine. The firm operates its businesses within the China market and to overseas markets such as Russia, Switzerland, Tunisia, Germany, South Korea and Japan.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 2 Sept 2020
- Employees
- 1,323
- Website
- eastonpharma.cn ↗
Leadership
Pay as last reported
- Ms. Ying WangChairman of the Board, since 2020CN¥1.4m
- Ms. Xiaoqin BoChief Financial Officer, Chief Accounting Officer, Director, since 2017
- Mr. Mingxu YuanGeneral Manager, Director, since 2020CN¥1.6m
- Mr. Zenggui ChenDeputy General Manager, Director, since 2021CN¥1.6m
- Mr. Daming ZhangDeputy General Manager, Director, since 2013CN¥1.1m
- Mr. Hong ChenDeputy General ManagerCN¥3.3m
- Mr. Zhengpin GuanDeputy General ManagerCN¥923,000
- Mr. Xingyao SongDeputy General ManagerCN¥840,500
- Mr. Xiaoxun LiChief Scientific Officer- Raw Materials Medicine
- Mr. Avinash RamkisanmaneChief Scientific Officer- Formulation Research Department
- Ms. Zhumei ShengChief Strategic Development Officer
- Ms. Shuyun LiSecretary of the Board
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Chengdu Easton Biopharmaceuticals employs 1,323 full-time employees in Chengdu, China.
- Chengdu Easton's products include nalmefene hydrochloride injection and ibuprofen injection for anesthesia and analgesia.
- Chengdu Easton operates in China and markets to Russia, Switzerland, Tunisia, Germany, South Korea, and Japan.
Weaknesses
- Chengdu Easton's products are limited to chemical generic drugs without mention of innovative therapies.
- Chengdu Easton's business is concentrated in China with limited international expansion beyond specific countries.
- Chengdu Easton's product portfolio lacks diversity in therapeutic areas beyond cardiovascular and anti-tumor.
Opportunities
- Chengdu Easton can expand its product line into new therapeutic areas like neurology or immunology.
- Chengdu Easton can leverage its presence in Germany and Japan to enter European and Asian markets.
- Chengdu Easton can increase sales in Russia and South Korea by expanding its product offerings.
Threats
- Chengdu Easton faces competition from other Chinese pharmaceutical companies in the domestic market.
- Chengdu Easton's reliance on chemical generic drugs may face regulatory challenges in international markets.
- Chengdu Easton's operations in China could be affected by economic downturns in the Chinese market.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.